BridgeBio Pharma Inc [BBIO] stock prices are down -1.15% to $62.64 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BBIO shares have gain 15.44% over the last week, with a monthly amount glided 17.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Truist started tracking the stock with Buy rating on July 21, 2025, and set its price target to $66. On July 14, 2025, Jefferies initiated with a Buy rating and assigned a price target of $70 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $60 on July 09, 2025. Wolfe Research initiated its recommendation with a Outperform and recommended $49 as its price target on June 17, 2025. Redburn Atlantic started tracking with a Buy rating for this stock on March 31, 2025, and assigned it a price target of $50. In a note dated October 16, 2024, Scotiabank initiated an Sector Outperform rating.
The stock price of BridgeBio Pharma Inc [BBIO] has been fluctuating between $21.72 and $69.48 over the past year. Currently, Wall Street analysts expect the stock to reach $83.71 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $62.64 at the most recent close of the market. An investor can expect a potential return of 33.64% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
The BridgeBio Pharma Inc [NASDAQ:BBIO] reported sales of 353.78M for trailing twelve months, representing a surge of 4318.01%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -1.79%, Pretax Profit Margin comes in at -2.35%, and Net Profit Margin reading is -2.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.8, Equity is 0.47 and Total Capital is -0.78. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 61.69 points at the first support level, and at 60.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 63.95, and for the 2nd resistance point, it is at 65.27.
Ratios To Look Out For
It’s worth pointing out that BridgeBio Pharma Inc [NASDAQ:BBIO]’s Current Ratio is 3.88. Further, the Quick Ratio stands at 3.76, while the Cash Ratio is 2.97. Considering the valuation of this stock, the price to sales ratio is 34.12.
Transactions by insiders
Recent insider trading involved MCCORMICK FRANK, Director, that happened on Oct 29 ’25 when 0.2 million shares were sold. Director, Frank McCormick completed a deal on Oct 29 ’25 to buy 0.2 million shares. Meanwhile, Director MCCORMICK FRANK sold 1641.0 shares on Oct 27 ’25.
